To address the model variability issue and gain deeper understanding on how CAR affinity for the targeted antigen might influence this pathway, we develop a preclinical model of tumor cell lines engineered to express different PD-L1 densities (absent, low, or high) for systematic interrogation of different CAR configurations both in vitro and in vivo. The gene discussed is CD274; the disease is neoplasm.